Bio-Rad Laboratories Celselect Slides validated antibodies for rare cell and CTC enumeration

Tuesday, 02 April, 2024 | Supplied by: Bio-Rad Laboratories Pty Ltd


Bio-Rad Laboratories has launched a range of validated antibodies for rare cell and circulating tumour cell (CTC) enumeration. Validated for use with the company’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumour heterogeneity and disease progression at various stages.

Bio-Rad’s Genesis Cell Isolation System is a customisable benchtop solution that uses unbiased size-based cell selection to gently and efficiently capture a wide range of CTCs and other rare cells from liquid biopsy samples. After capture, the enriched cells can be recovered for downstream analysis or immuno-stained on-slide for immunofluorescence applications such as enumeration and identification of various CTC types.

The enumeration of captured CTCs provides valuable insights into the surface markers that indicate cancer type and progression, and is critical to understanding the mechanisms of cancer metastasis. For successful enumeration, the antibody reagents require careful selection to ensure not only sensitivity and specificity to the target cell surface marker, but also compatibility with the staining method. Bio-Rad’s range of validated primary and secondary antibodies enables immunostaining of captured CTCs, supporting cancer researchers working in this field.

Online: www.bio-rad.com
Phone: 02 9914 2800
Related Products

Integrated DNA Technologies xGen Hybridization and Wash v3 Kit

Integrated DNA Technologies (IDT) has unveiled its xGen Hybridization and Wash v3 Kit — a...

Cytek Tonbo Reagents

Cytek Tonbo Reagents are designed to enable high-quality research without breaking the budget....

Selleck Chemicals FDA-approved Anticancer Drug Library

Selleck Chemicals (SelleckChem) offers a collection of 1734 approved drugs with potential...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd